Skip to main content
. Author manuscript; available in PMC: 2022 Jul 25.
Published in final edited form as: J Acquir Immune Defic Syndr. 2021 Jun 1;87(2):875–881. doi: 10.1097/QAI.0000000000002657

Figure 1.

Figure 1

Competitive Luminex immunoassay titers to HPV-6/11/16 and 18 at baseline, week 28 and week 52 in the per-protocol population. Points represent median; error bar IQR

Group 1: CD4 nadir ≤ 350 cells/mm3, on ART

Group 2: CD4 nadir >350 cells/mm3, current CD4 between 350 cells/mm3 and 500 cells/mm3, not on ART

Group 3: CD4 nadir > 350 cells/mm3, current CD4 > 500 cells/mm3, not on ART